News Column

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Provectus Biopharmaceuticals,...

July 26, 2014



INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Provectus Biopharmaceuticals, Inc.

By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company") (NYSE:PVCT) between December 17, 2013 and May 22, 2014, inclusive (the "Class Period") have until July 28, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit (see also Law Offices of Howard G. Smith).

Provectus is a development-stage biopharmaceutical company engaged in developing pharmaceuticals for oncology and dermatology indications. The Company's product line includes PV-10, which has completed a Phase II study for metastatic melanoma and a Phase I study for breast cancer, and is in various stages of clinical development for certain other cancer indications. The Complaint alleges that defendants misrepresented and/or failed to disclose material adverse facts concerning the status of PV-10 and preparations for a Phase III study of the drug.

On May 23, 2014, the Company announced that its application for a designation of PV-10 as a "Breakthrough Therapy" was denied by the Food and Drug Administration. According to the Company, the FDA denied the designation because the agency's review indicated that "the data upon which the Company based its request for designation of PV-10 as a Breakthrough Therapy for the treatment of patients with locally advanced cutaneous melanoma was insufficient to demonstrate substantial improvement over existing therapies."

If you are a member of the Class described above, you may move the Court no later than July 28, 2014, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

Keywords for this news article include: Drugs, Therapy, Legal Issues, Biopharmaceuticals, Law Offices of Howard G. Smith.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Obesity, Fitness & Wellness Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters